BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24976335)

  • 1. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.
    Luo SY; Sit KY; Sihoe AD; Suen WS; Au WK; Tang X; Ma ES; Chan WK; Wistuba II; Minna JD; Tsao GS; Lam DC
    Lung Cancer; 2014 Aug; 85(2):282-92. PubMed ID: 24976335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
    Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
    Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.
    Wan L; Sun M; Liu GJ; Wei CC; Zhang EB; Kong R; Xu TP; Huang MD; Wang ZX
    Mol Cancer Ther; 2016 May; 15(5):1082-94. PubMed ID: 26908628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations.
    Kohno M; Okamoto T; Suda K; Shimokawa M; Kitahara H; Shimamatsu S; Konishi H; Yoshida T; Takenoyama M; Yano T; Maehara Y
    Clin Cancer Res; 2014 Jul; 20(13):3613-22. PubMed ID: 24803578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
    Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
    Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
    Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
    Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice.
    Li A; Zhang C; Gao S; Chen F; Yang C; Luo R; Xiao H
    Oncogene; 2013 May; 32(18):2273-81, 2281e.1-12. PubMed ID: 22733137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
    Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
    Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
    Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.
    Toki MI; Carvajal-Hausdorf DE; Altan M; McLaughlin J; Henick B; Schalper KA; Syrigos KN; Rimm DL
    J Thorac Oncol; 2016 Nov; 11(11):1901-1911. PubMed ID: 27449805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
    Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
    Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.